Abstract: Doxorubicin (DOX), an anthracycline antibiotic, remains one of the most potent and widely utilized chemotherapeutic agents for the treatment of various solid tumors and hematological malignancies. Despite its broad-spectrum efficacy, the clinical application of DOX is severely hindered by dose-limiting adverse effects, most notably irreversible cardiotoxicity, as well as the development of multidrug resistance (MDR). To overcome these critical barriers, targeted delivery systems and nanomedicine have emerged as transformative strategies in oncology. This review provides a comprehensive overview of DOX, detailing its pharmacological activity, molecular mechanisms of action, and structure-activity relationships that facilitate its integration into advanced nanocarriers. Furthermore, we discuss the current limitations of conventional DOX therapy and highlight future perspectives in nanomedicine. Emerging platforms such as polymeric micelles, dendrimers, hydrogels, and stimuli-responsive nanoparticles offer promising avenues to enhance tumor-specific accumulation, improve pharmacokinetic profiles, and minimize systemic toxicity, thereby maximizing the therapeutic index of DOX.
1. Introduction
Cancer remains a leading cause of mortality globally, characterized by the uncontrolled proliferation of abnormal cells. While conventional treatments such as surgery, radiation, and chemotherapy are standard, they are often limited by severe systemic toxicities and the development of drug resistance [1]. Doxorubicin (DOX), originally isolated from Streptomyces peucetius in the 1960s, is a cornerstone of modern cancer chemotherapy [7][10]. As a highly effective anthracycline, DOX is integrated into numerous treatment regimens; however, its lack of specificity leads to the destruction of healthy, fast-dividing cells, resulting in myelosuppression, nausea, and severe cumulative cardiotoxicity [1][12].
To mitigate these adverse effects while preserving antitumor efficacy, the field of pharmaceutical nanotechnology has heavily focused on DOX. By entrapping or conjugating the drug within biocompatible nanocarriers, researchers aim to improve its aqueous solubility, prolong its circulation time, and facilitate targeted delivery to the tumor microenvironment [2]. The development of the first FDA-approved nanodrug, Doxil® (pegylated liposomal doxorubicin), marked a significant milestone in this endeavor, proving that nanomedicine can successfully alter the pharmacokinetic profile of DOX to reduce cardiotoxicity [2][9]. Today, the evolution of DOX delivery systems continues, shifting from basic liposomes to sophisticated, stimuli-responsive, and actively targeted polymeric nanocarriers [2][8].
2. Pharmacological Activity
Doxorubicin exhibits a broad spectrum of pharmacological activity and is employed as a first-line treatment for a wide array of malignancies. Its clinical indications include breast cancer, ovarian cancer, lung cancer, bladder cancer, gastric cancer, soft tissue sarcomas, osteosarcoma, leukemias, and Hodgkin’s lymphoma [7][10][13]. The drug is often administered alone or in combination with other cytotoxic agents (such as cyclophosphamide or paclitaxel) to maximize tumor eradication [7][10].
The pharmacological success of DOX has driven the development of various commercial nanoformulations designed to maintain its potent activity while improving patient safety. Formulations such as Doxil®/Caelyx® (pegylated liposomes) and Myocet® (non-pegylated liposomes) have demonstrated comparable or improved efficacy in metastatic breast and ovarian cancers, primarily by leveraging the enhanced permeability and retention (EPR) effect to accumulate in tumor tissues [1][7]. Despite these advancements, the core pharmacological challenge remains balancing the aggressive eradication of cancer cells with the preservation of healthy organ function [2].
3. Molecular Mechanism of Action
The anticancer efficacy of DOX is attributed to a pleiotropic mechanism of action that disrupts cellular replication and induces cell death. Primarily, DOX intercalates into the DNA double helix and inhibits the enzyme topoisomerase II. This action prevents DNA unwinding, stalls transcription and replication, and ultimately leads to DNA double-strand breaks [1][7][11]. Additionally, DOX is known to induce histone eviction from open chromatin, further destabilizing the genomic structure of cancer cells [2].
Beyond direct DNA interaction, DOX generates reactive oxygen species (ROS) through redox cycling. This massive production of ROS induces severe oxidative stress, which damages lipid membranes, proteins, and DNA, triggering apoptosis [5][7]. Emerging evidence also points to DOX's involvement in other cellular pathways, including the induction of senescence, autophagy, ferroptosis, and pyroptosis, as well as playing an immunomodulatory role in the tumor microenvironment [5]. Unfortunately, these mechanisms—particularly ROS generation and topoisomerase inhibition—are not selective to neoplastic cells, which directly contributes to the drug's profound toxicity in healthy cardiac myocytes [11].
4. Structure-Activity Relationship (SAR)
The chemical structure of DOX is fundamental to both its cytotoxic activity and its adaptability for nanomedicine. DOX is an anthracycline antibiotic consisting of a rigid, hydrophobic tetracyclic aglycone (four anthraquinone rings) linked via a glycosidic bond to a hydrophilic amino sugar moiety (daunosamine) [1]. The planar anthraquinone rings are responsible for the drug's ability to intercalate between DNA base pairs, while the amino sugar facilitates binding to the sugar-phosphate backbone of DNA [1].
From a drug delivery perspective, the functional groups on DOX—specifically the primary amine on the sugar moiety and the hydroxyl/carbonyl groups on the aglycone—provide versatile sites for chemical modification and conjugation. While DOX can be physically entrapped in nanocarriers via non-covalent interactions (electrostatic, van der Waals, or hydrogen bonding), covalent conjugation offers superior stability and higher drug loading capacities [6]. DOX is frequently conjugated to polymers or nanoparticles via:
- Amide bonds: Formed by coupling the amine group of DOX with carboxyl groups on the carrier, often facilitated by carbodiimide reagents [6].
- Hydrazone bonds: Formed between hydrazines and the carbonyl groups of DOX, providing a pH-sensitive linkage that remains stable in circulation but cleaves rapidly in the acidic environment of tumor endosomes/lysosomes [6].
- Disulfide bonds: Utilized for redox-responsive release, as these bonds are cleaved by high intracellular concentrations of reducing agents like glutathione (GSH) found in cancer cells [6].
5. Current Limitations
Despite its clinical indispensability, DOX therapy is severely restricted by several critical limitations:
- Systemic Toxicity: The most prominent and dangerous side effect is doxorubicin-induced cardiotoxicity (DIC), which is cumulative, dose-dependent, and can lead to irreversible cardiomyopathy and fatal heart failure [2][9][11]. DOX also induces significant hepatotoxicity, nephrotoxicity, neurotoxicity, and gonadotoxicity [3][14].
- Multidrug Resistance (MDR): Cancer cells frequently develop resistance to DOX. Because DOX enters cells via passive diffusion, it is highly susceptible to efflux by overexpressed ATP-binding cassette transporters, such as P-glycoprotein (P-gp), which actively pump the drug out of the cell, neutralizing its efficacy [2][6].
- Physicochemical Constraints: DOX suffers from poor water solubility and a short biological half-life, complicating its formulation and requiring frequent dosing [2][8].
- Limitations of Current Nanomedicines: While first-generation liposomal formulations like Doxil® reduce cardiotoxicity, they introduce new adverse effects, such as palmar-plantar erythrodysesthesia (hand-foot syndrome). Furthermore, they often suffer from limited cellular uptake, poor tissue penetration, and slow, uncontrolled drug release at the tumor site [2][9].
6. Future Perspectives
To overcome the limitations of free DOX and first-generation liposomes, the future of DOX therapy lies in the development of advanced, multifunctional nanocarriers. Polymeric nanocarriers—including polymeric micelles, dendrimers, hydrogels, and polymer-drug conjugates—are at the forefront of this research due to their tunable properties, ease of fabrication, and excellent biocompatibility [2][10].
Stimuli-Responsive Systems: Next-generation carriers are being engineered to release DOX only upon encountering specific triggers. Internal stimuli-responsive systems exploit the unique tumor microenvironment, such as acidic pH, elevated reactive oxygen species, high glutathione levels, or overexpressed enzymes (e.g., cathepsin B) to trigger drug release [3][8]. External stimuli, including magnetic fields, ultrasound, and photo-thermal triggers, are also being investigated to provide precise spatial and temporal control over DOX release [8][12].
Active Targeting: To enhance cellular internalization and bypass P-gp-mediated efflux, nanocarriers are being decorated with targeting ligands. Molecules such as folic acid, hyaluronic acid, peptides (e.g., RGD), aptamers, and monoclonal antibodies (e.g., Herceptin for HER2+ breast cancer) allow nanoparticles to bind specifically to receptors overexpressed on cancer cells, facilitating receptor-mediated endocytosis [3][12][13].
Combination Therapy and Co-delivery: Nanoplatforms enable the simultaneous delivery of DOX with other therapeutic agents. Co-encapsulation of DOX with antioxidants (to mitigate oxidative stress in healthy tissues), chemosensitizers, or natural products (e.g., resveratrol, quercetin, curcumin) shows immense promise in reversing MDR and protecting against cardiotoxicity [2][3].
While the preclinical results for these advanced DOX delivery systems are highly encouraging, future efforts must address the challenges of manufacturing scalability, carrier immunogenicity, and the complex regulatory pathways required for clinical translation [2][4]. Continued innovation in nanomedicine holds the key to unlocking the full therapeutic potential of doxorubicin while safeguarding patient health.
